Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer

Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by... Purpose This phase II study was performed to evaluate the efficacy and safety of cisplatin/pemetrexed combined with 15 mg/ kg of bevacizumab followed by pemetrexed/bevacizumab maintenance therapy as first-line chemotherapy in advanced non- squamous non-small cell lung cancer (NSCLC) limited to epidermal growth factor receptor (EGFR)-wild type. Patients and methods Fifty patients with advanced or metastatic EGFR-wild type NSCLC aged < 75 years old were enrolled 2 2 in the study. The patients were treated with four cycles of cisplatin (75 mg/m , day 1), pemetrexed (500 mg/m , days 1), and bevacizumab (15 mg/kg, day 1), every 3 weeks, followed by pemetrexed plus bevacizumab maintenance until progression for achieving a response over stable disease after induction chemotherapy. Results Partial response and stable disease were observed in 35 (objective response rate: 70, 95% CI: 55.4–82.1%) and 9 patients, respectively, and 39 (78%) patients received pemetrexed plus bevacizumab maintenance therapy. Median progres- sion-free survival and overall survival periods were 12.0 months (95% CI: 7.5–16.5 months) and 31.0 months (95% CI: 22.2–39.8 months), respectively. Grade 3 adverse events included neutropenia (14%), nausea (10%), anorexia (18%), and hypertension (8%). Coagulation disorder was observed in one patient, but all of these events were reversible and resulted in no http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Chemotherapy and Pharmacology Springer Journals

Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer

Loading next page...
 
/lp/springer_journal/phase-ii-study-of-cisplatin-pemetrexed-combined-with-bevacizumab-Rhw6MHT1Kv
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Pharmacology/Toxicology; Cancer Research
ISSN
0344-5704
eISSN
1432-0843
D.O.I.
10.1007/s00280-018-3573-0
Publisher site
See Article on Publisher Site

Abstract

Purpose This phase II study was performed to evaluate the efficacy and safety of cisplatin/pemetrexed combined with 15 mg/ kg of bevacizumab followed by pemetrexed/bevacizumab maintenance therapy as first-line chemotherapy in advanced non- squamous non-small cell lung cancer (NSCLC) limited to epidermal growth factor receptor (EGFR)-wild type. Patients and methods Fifty patients with advanced or metastatic EGFR-wild type NSCLC aged < 75 years old were enrolled 2 2 in the study. The patients were treated with four cycles of cisplatin (75 mg/m , day 1), pemetrexed (500 mg/m , days 1), and bevacizumab (15 mg/kg, day 1), every 3 weeks, followed by pemetrexed plus bevacizumab maintenance until progression for achieving a response over stable disease after induction chemotherapy. Results Partial response and stable disease were observed in 35 (objective response rate: 70, 95% CI: 55.4–82.1%) and 9 patients, respectively, and 39 (78%) patients received pemetrexed plus bevacizumab maintenance therapy. Median progres- sion-free survival and overall survival periods were 12.0 months (95% CI: 7.5–16.5 months) and 31.0 months (95% CI: 22.2–39.8 months), respectively. Grade 3 adverse events included neutropenia (14%), nausea (10%), anorexia (18%), and hypertension (8%). Coagulation disorder was observed in one patient, but all of these events were reversible and resulted in no

Journal

Cancer Chemotherapy and PharmacologySpringer Journals

Published: Apr 11, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off